NCT03678883 2024-11-079-ING-41 in Patients with Advanced CancersActuate Therapeutics Inc.Phase 2 Active not recruiting350 enrolled
NCT03878524 2024-03-04Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialOHSU Knight Cancer InstitutePhase 1 Terminated2 enrolled
NCT03567720 2023-06-01Tavo and Pembrolizumab With or Without Chemotherapy in Patients With Inoperable Locally Advanced or Metastatic TNBCOncoSec Medical IncorporatedPhase 2 Unknown65 enrolled
NCT00140140 2019-11-26A Phase I/II Study of ABI-007 (Abraxane®, Nab®-Paclitaxel)and Vinorelbine in Patients With Stage IV (Metastatic) Breast CancerCelgenePhase 1/2 Terminated16 enrolled 21 charts
NCT00281528 2019-11-22Weekly vs. Every 2 Week vs. Every 3 Week Administration of ABI-007 (Abraxane)/Bevacizumab Combination in Metastatic Breast CancerCelgenePhase 2 Terminated208 enrolled 23 charts
NCT01929941 2018-01-17An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced MalignanciesIncyte CorporationPhase 1 Terminated5 enrolled
NCT00046514 2016-12-15ABI-007 in Taxol Resistant Patients With Metastatic Breast CancerCelgene CorporationPhase 2 Completed100 enrolled
NCT00607438 2012-05-11A Phase II Study Of Abraxane and Nexavar in the First-Line Treatment of Locally Advanced or Metastatic Breast CancerVeeda OncologyPhase 2 Terminated16 enrolled
NCT00046527 2006-07-13Study of ABI-007 and Taxol in Patients With Metastatic Breast CancerCelgene CorporationPhase 3 Completed460 enrolled